Creative Medical Technology Holdings, Inc
Creative Medical Technology Holdings, Inc. is a commercial-stage biotechnology company built around a portfolio of regenerative medicine and cell-therapy concepts. The company traces its roots to intellectual property originally acquired for erectile dysfunction treatment and has since expanded into immune-cell reprogramming and stem-cell-based programs across urology, endocrinology, neurology, orthopedics, and other disease areas. Its operating model is still largely development-focused, with research, clinical trials, and IP monetization driving the business rather than meaningful product sales. The company also uses subsidiaries such as ImmCelz, StemSpine, and AlloCelz to organize its therapeutic platforms and development programs.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAutologous and reprogrammed-cell therapies developed under the ImmCelz platform and related programs.
Human trials and translational programs such as CELZ-201 for pain and metabolic disease.
Patent-backed assets and disease-specific IP originally centered on erectile dysfunction and expanded indications.
Small-scale revenue-generating activities and related offerings that have not yet become a core business.
Customers
The company’s direct customers are limited because most of its programs are still in development, so the main economic counterparties are clinical trial participants, research collaborators, and industry partners rather than large commercial buyers. In the near term, value is created for physicians, investigators, and partner organizations that support trials in pain, diabetes, urology, and other regenerative medicine indications. If programs advance successfully, future customers would likely include hospitals, specialty clinics, and healthcare providers using approved therapies. The company also depends on investors and capital markets to fund development, which is a critical part of the business model for an early commercial biotechnology company.
Patients enrolled in studies for chronic lower back pain, diabetes, and other indications to generate safety and efficacy data.
Collaborators that help advance preclinical work, trial execution, and translational development of cell-based therapies.
Potential future buyers of approved regenerative or biologic therapies if programs reach commercialization.
Equity investors and warrant holders that provide funding for R&D, public-company costs, and clinical advancement.
Strategy
The company’s strategy is to advance its regenerative medicine pipeline through clinical data generation, starting with programs such as CELZ-201 in chronic lower back pain and related indications. Management is also broadening the platform beyond the original erectile dysfunction IP into immune-cell reprogramming and stem-cell-based therapies across multiple disease areas. Near-term execution depends on completing cohorts, analyzing safety and efficacy data, and using those results to guide regulatory and development plans. Because the business is still pre-scale, capital raising and disciplined allocation of R&D spending are central to maintaining momentum.
Clinical data is the main value driver for a biotechnology company with limited commercial revenue.
Diversification across pain, diabetes, urology, neurology, and orthopedics reduces dependence on any single program.
The company is cash-consuming and relies on external capital to continue development.
Geography
The company is headquartered in Phoenix, Arizona, and its reported operations are primarily U.S.-based. The available filings do not disclose a meaningful country revenue split, which is consistent with a development-stage biotechnology company that has not built a broad commercial footprint. Its clinical and research activities appear centered on U.S. programs and U.S. capital markets access. Geography matters mainly through regulatory oversight, clinical trial execution, and the concentration of operating costs in the United States.
Risks
The company faces the classic risks of an early-stage biotechnology developer: clinical failure, regulatory delays, and uncertainty around whether early safety signals will translate into durable efficacy. Its programs are still in development, so the business depends on successful trial execution and the ability to raise capital before meaningful product revenue exists. The recent financing activity shows ongoing dilution and warrant-related complexity, which can affect shareholder returns and capital structure. More broadly, biotechnology companies are exposed to scientific, reimbursement, intellectual property, and public-market financing risks, all of which can materially affect valuation and operating continuity.
The company’s value depends on translating early-stage data into successful human trial outcomes and eventual approvals.
Operations consume cash and the company has relied on warrant exercises and equity-linked financing to fund development.
Clinical and regulatory plans depend on cohort data, safety reviews, and agency feedback that can change timelines materially.
Exposure: U.S. clinical development programs
The company’s origin and differentiation are tied to patents and related IP, which must remain enforceable and relevant.
Exposure: ED-related IP and broader platform assets
Accounting
Judgemental itemsThe March 2025 transaction required valuation of existing and new warrants and affected additional paid-in capital and deemed dividend presentation.
Impact: Can materially change equity balances and reported financing-related items
Clinical trial and partner-related spending shifts between quarters, driving large swings in operating loss.
Impact: Affects comparability of quarterly results and cash burn analysis
The company must estimate the fair value of warrants and related inducements using judgmental inputs.
Impact: Can create non-cash charges or equity adjustments
Similar listed companies
Publicly listed companies with a comparable business focus.
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CERO · Biological Products, (No Diagnostic Substances)
Celularity Inc
CELU · Pharmaceutical Preparations
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
BriaCell Therapeutics Corp.
BCTX · Pharmaceutical Preparations
Prime Medicine, Inc.
PRME · Biological Products, (No Diagnostic Substances)
Last updated: 11/08/2026